Stromal Caveolin-1 and Caveolin-2 Expression in Primary Tumors and Lymph Node Metastases

Table 3

Correlation between caveolin-2 expression in lung cancer stroma and clinical parameters.

	Total	Negative		Weak		Strong		value
	n	n	%	n	%	n	%
All	150	35	23.3	46	30.7	69	46.0
Sex								0.41
Female	25	6	24	5	20	14	56
Male	125	29	23	41	33	55	44
Age								0.60
<MW	73	20	27	21	29	32	44
>MW	74	15	20	23	31	36	49
n.a.	3
Histology								0.36
SCC	70	13	19	21	30	36	51
AC	59	14	24	22	37	23	39
LCLC	10	4	40	1	10	5	50
Others	11	4	26	2	18	5	45
Grade combined								0.57
G1 + 2	66	13	20	19	29	34	52
G3 + 4	75	18	24	25	33	32	43
n.a.	9
Tumor size								0.86
pT1	28	7	25	8	29	13	46
pT2	90	20	22	28	31	42	47
pT3	22	6	27	5	23	11	50
pT4	8	2	25	4	50	2	25
n.a.	2
Lymph node status								0.84
pN0	75	17	23	24	32	34	45
pN1	45	11	24	11	24	23	51
pN2 + 3	27	6	22	10	37	11	41
n.a.	3
Distant metastasis								0.76
pM0	137	32	23	42	31	63	46
pM1	10	3	30	2	20	5	50
n.a.	3
UICC stage								1.00
IA + B	68	16	24	21	31	31	46
IIA + B	36	8	22	11	31	17	47
IIIA + B	33	8	24	10	30	15	46
IV	10	3	30	2	20	5	50
n.a.	3
Death								0.61
No	36	7	19	13	36	16	45
Yes	110	28	26	31	28	51	46
n.a.	4
Smoking								0.57
Current	66	19	29	15	23	32	49
Ex-smoker	66	16	24	22	33	28	42
None	3	0	0	1	33	2	67
n.a.	15
Asbestos								0.28
No	84	22	26	20	24	42	50
Yes	47	12	26	17	36	18	38
n.a.	19

n.a.: not available; ex-smoker: quit smoking > 6 months prior to surgery.